Acquired haemophilia A: A 2013 update

Massimo Franchini, Pier Mannuccio Mannucci

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Acquired haemophilia A (AHA) is a rare but often severe bleeding disorder caused by autoantibodies against coagulation factor VIII (FVIII). AHA occurs more frequently in the elderly and in association with several conditions, such as the post-partum period, malignancies, autoimmune diseases or drug exposure; however, approximately 50% of reported cases are apparently idiopathic. Beside the elimination of the underlying disorder, the therapeutic approach to AHA should be directed toward the control of acute bleed and the eradication of FVIII autoantibody production. In this narrative review, we summarise the current knowledge on the epidemiology, diagnosis and clinical features of AHA, focusing in particular on advances in the management of this challenging bleeding disorder.

Original languageEnglish
Pages (from-to)1114-1120
Number of pages7
JournalThrombosis and Haemostasis
Volume110
Issue number6
DOIs
Publication statusPublished - Sep 5 2013

Fingerprint

Factor VIII
Autoantibodies
Elimination Disorders
Hemorrhage
Autoimmune Diseases
Epidemiology
Acquired Factor 8 deficiency
Pharmaceutical Preparations
Neoplasms
Therapeutics

Keywords

  • Acquired haemophilia A
  • Auto-antibodies
  • Bleeding
  • FVIII
  • Inhibitors
  • Therapy

ASJC Scopus subject areas

  • Hematology

Cite this

Acquired haemophilia A : A 2013 update. / Franchini, Massimo; Mannucci, Pier Mannuccio.

In: Thrombosis and Haemostasis, Vol. 110, No. 6, 05.09.2013, p. 1114-1120.

Research output: Contribution to journalArticle

Franchini, Massimo ; Mannucci, Pier Mannuccio. / Acquired haemophilia A : A 2013 update. In: Thrombosis and Haemostasis. 2013 ; Vol. 110, No. 6. pp. 1114-1120.
@article{d7bc26707d0149a29b6017dc28656c99,
title = "Acquired haemophilia A: A 2013 update",
abstract = "Acquired haemophilia A (AHA) is a rare but often severe bleeding disorder caused by autoantibodies against coagulation factor VIII (FVIII). AHA occurs more frequently in the elderly and in association with several conditions, such as the post-partum period, malignancies, autoimmune diseases or drug exposure; however, approximately 50{\%} of reported cases are apparently idiopathic. Beside the elimination of the underlying disorder, the therapeutic approach to AHA should be directed toward the control of acute bleed and the eradication of FVIII autoantibody production. In this narrative review, we summarise the current knowledge on the epidemiology, diagnosis and clinical features of AHA, focusing in particular on advances in the management of this challenging bleeding disorder.",
keywords = "Acquired haemophilia A, Auto-antibodies, Bleeding, FVIII, Inhibitors, Therapy",
author = "Massimo Franchini and Mannucci, {Pier Mannuccio}",
year = "2013",
month = "9",
day = "5",
doi = "10.1160/TH13-05-0363",
language = "English",
volume = "110",
pages = "1114--1120",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "6",

}

TY - JOUR

T1 - Acquired haemophilia A

T2 - A 2013 update

AU - Franchini, Massimo

AU - Mannucci, Pier Mannuccio

PY - 2013/9/5

Y1 - 2013/9/5

N2 - Acquired haemophilia A (AHA) is a rare but often severe bleeding disorder caused by autoantibodies against coagulation factor VIII (FVIII). AHA occurs more frequently in the elderly and in association with several conditions, such as the post-partum period, malignancies, autoimmune diseases or drug exposure; however, approximately 50% of reported cases are apparently idiopathic. Beside the elimination of the underlying disorder, the therapeutic approach to AHA should be directed toward the control of acute bleed and the eradication of FVIII autoantibody production. In this narrative review, we summarise the current knowledge on the epidemiology, diagnosis and clinical features of AHA, focusing in particular on advances in the management of this challenging bleeding disorder.

AB - Acquired haemophilia A (AHA) is a rare but often severe bleeding disorder caused by autoantibodies against coagulation factor VIII (FVIII). AHA occurs more frequently in the elderly and in association with several conditions, such as the post-partum period, malignancies, autoimmune diseases or drug exposure; however, approximately 50% of reported cases are apparently idiopathic. Beside the elimination of the underlying disorder, the therapeutic approach to AHA should be directed toward the control of acute bleed and the eradication of FVIII autoantibody production. In this narrative review, we summarise the current knowledge on the epidemiology, diagnosis and clinical features of AHA, focusing in particular on advances in the management of this challenging bleeding disorder.

KW - Acquired haemophilia A

KW - Auto-antibodies

KW - Bleeding

KW - FVIII

KW - Inhibitors

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84888426309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888426309&partnerID=8YFLogxK

U2 - 10.1160/TH13-05-0363

DO - 10.1160/TH13-05-0363

M3 - Article

C2 - 24008306

AN - SCOPUS:84888426309

VL - 110

SP - 1114

EP - 1120

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 6

ER -